Your own immune cells, re-engineered into a targeted cancer treatment — and infused back as a single dose.
CAR-T stands for Chimeric Antigen Receptor T-cell therapy. It is a type of immunotherapy that takes a patient's own T cells — a kind of white blood cell that fights disease — and reprograms them in the laboratory to recognize a specific marker (antigen) on cancer cells.
T cell → add a synthetic receptor (CAR) → multiply → infuse → seek & destroy cancer
Before CAR-T, many patients with relapsed or refractory blood cancers had exhausted every standard option. CAR-T has produced complete remissions in people for whom chemotherapy, targeted drugs and stem-cell transplants had failed.
Because the engineered cells can persist in the body for months or years, they may continue to guard against the cancer long after a single infusion — which is why CAR-T is often described as a "living drug."
How the cells are made →Understanding how CAR-T differs helps patients and families set realistic expectations.
| Aspect | Chemotherapy / Radiation | CAR-T Cell Therapy |
|---|---|---|
| What it targets | All rapidly dividing cells (including healthy ones) | A specific cancer marker (e.g. CD19, BCMA) |
| Source | Manufactured drug given repeatedly | The patient's own cells, engineered individually |
| Course | Multiple cycles over weeks/months | Typically a single infusion |
| Durability | Effect stops when treatment ends | Engineered cells may persist and protect for years |
| Key risks | Suppressed immunity, hair loss, nausea | CRS, ICANS (mostly manageable in expert centers) |
A white blood cell of the immune system. CAR-T starts with these cells collected from the patient's blood.
A synthetic protein added to the T cell so it can "see" and bind a specific antigen on cancer cells.
The marker the CAR recognizes — most commonly CD19 (B-cell cancers) or BCMA (myeloma).
Cytokine Release Syndrome — a fever/inflammatory response after infusion, usually manageable with dedicated care.
Immune Effector Cell-Associated Neurotoxicity — a temporary neurological effect, monitored closely by the team.
Disappearance of detectable disease — the primary goal, achieved in many relapsed/refractory cases.
Most approved CAR-T today uses the patient's own cells (autologous). The next frontier is allogeneic CAR-T from donor cells, which could be ready without a weeks-long manufacturing wait.
Made from the patient's own T cells. Highly personalized; requires a manufacturing period of a few weeks between collection and infusion.
Built from healthy donor cells and engineered to be "universal." Aim: off-the-shelf availability. Mostly still in trials, with some early approvals emerging.